HAILEY RAY

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information. H.R. 6832 PACK Act (Packaging and Claims Knowledge Act)

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings. H.R. 7502 Recycled Materials Attribution Act (RMAA)

General issues related to the manufacturing and supply chain resiliency of over-the-counter medications, specifically as it relates to additional domestic production of healthcare products; General monitor and review of legislative and administrative action related to domestic supply chain and manufacturing capabilities. H.R. 7502 Recycled Materials Attribution Act (RMAA)

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.

General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter.

H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter.

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of issues related to federal tax amortization of research and development expenses; General review and monitoring of issues that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of issues and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA; Continued monitor and review of fiscal year (FY) 2025 budget resolution in both House and Senate, along with associated reconciliation instructions.

General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)

General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)

H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act

Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth

H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.

General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)

H.R. 6284 Improving Measurements for Loneliness and Isolation Act General review of federal policies applying towards paid family and medical leave. General review of legislative and administration action related to pediatric over-the-counter concerns.

Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth

General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)

General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)

General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)

H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act

General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)

General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)

General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)

General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)

Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth